“A thorough and updated overview of BCa for any clinician involved in multidisciplinary care”

06 February 2019

After a successful inaugural meeting last year in Munich, the EAU is continuing to offer a two-day educational update on the topic of bladder cancer. The meeting is specifically designed to give participants a practical, high-quality and comprehensive update on bladder cancer, using highly interactive group-based case discussions to illustrate the latest treatment options.

BCa19 is coming to the North of Italy, to the historic and cultural city of Turin on 17-18 May, 2019. We spoke to Prof. Paolo Gontero (Turin, IT), member of the BCa19 Scientific Committee.

An interactive meeting

“We’ve designed the BCa19 scientific programme to appeal to any clinician involved in the multidisciplinary care of bladder cancer who wants to have a thorough and updated overview of the disease,” Gontero explains. “The format is designed to provide high quality, comprehensive information with a constant view to the clinical applicability of the contents.”

Aside from state of the art lectures that address all the meeting’s participants, the programme features three case discussion sessions. During these sessions, participants are assigned to a session room and they are joined in turn by three faculty groups, each addressing different aspects of bladder cancer.

For example, the first case discussion session offers the following three topics: Open vs robotic radical cystectomy, the possible benefit of extended lymphadenectomy in BCa, and a multidisciplinary look at the choice of urinary diversion. Participants can therefore enjoy the educational benefits of a smaller group, as well voting during the case discussions.

BCA19 features pre- and post-meeting testing. Prof. Gontero: “The mission of the meeting is thus to provide a high educational content, always oriented to clinical practice in order to fulfil the interest of clinicians that might have different levels of expertise.”

“This year the scientific committee has worked very hard to identify contents, titles of presentations and an outstanding faculty able to fulfil the interest of a multidisciplinary audience. The aim is to foster a high level of interest for all different topics among oncologists, radiotherapists and urologists. We believe that the methodology to conduct a high-standard TURBT is no less interesting for an oncologist or a radiotherapist than systemic immunotherapy is for a urologist.”

The character of the meeting

BCa19 is hardly the only oncology-related meeting that the EAU has to offer in 2019. It joins PCa19 and RCC19 in the onco-urology update series, as well as the ESOU’s annual section meeting and EMUC19. Prof. Gontero makes the distinction between BCa19 and its ‘cousins’:

“ESOU and EMUC are both outstanding meetings addressing the whole spectrum of uro-oncology, the latter with a special view to multidisciplinarity. However, the growing complexity and rapid progress in diagnostics and treatment of oncological diseases is generating the need of specialists devoted to a specific disease and this has translated into the dissemination of so-called bladder cancer clinics worldwide. BCa19 is the EAU meeting entirely devoted to train or to provide an annual update to bladder cancer specialists.”

In terms of topics addressed, Gontero pointed out some highlights:

“Genetics and, chiefly, molecular staging are changing the landscape of bladder cancer and Eva Prof. Eva Compérat (Paris, FR) and Prof. James Catto (Sheffield, GB) will have the task to explain how these new developments will soon affect clinical practice.”

“Another important issue is represented by the variant hystologies with Dr. Ashish Kamat (Houston, USA) and Dr. Shahrokh Shariat (Vienna, AT) translating these complex cases into practical management. Bladder cancer has recently witnessed technological advances in diagnostics as well as the consolidations and expansion of novel treatment options. These will be thoroughly covered.”

“The surgical topics will be devoted to a thorough discussion of controversial topics such as robotic and open cystectomy, the extent of lympadenectomy and the difficult choice of urine diversion.”

Optional Live Surgery Session

In addition to the full BCA19 scientific programme, Prof. Gontero is offering visitors to Turin the option to attend a special live surgery session, held on May 16, the day before BCA19 starts. Attending the live surgery session is free of charge for BCA19 delegates, although any extra night in Turin will be at delegates’ own expense.

“With the simultaneous satellite connection of three surgical theatres in the auditorium of Molinette Hospital in Turin, the whole afternoon preceding the meeting will be devoted to live procedures that address most of the topics that will be discussed in the following days during the meeting.”

“The simultaneous performance of an open and a robotic cystectomy with neobladder in 2 separate theatres will also offer the opportunity to view different extents of lymphadenectomy and urine diversions performed by the faculty. In another theatre, step-by-step TURBTs and upper tract diagnostics will be performed, employing standard and new surgical techniques. We will also demonstrate innovative new technologies such as Cellvizio.”

“Having a live surgery session entirely devoted to urothelial cancer procedures just preceding the meeting where the same procedures will be discussed is another good reason not to miss Bca19!”

What to expect:

  • Three operating theatres broadcasting simultaneous bladder procedures
  • Comparison of open and robotic cystectomy with neobladder
  • Demonstration of new technologies like Cellvizio

The Live Surgery Session “Standard and Innovative Procedures for Bladder Cancer in 2019” will take place on 16 May, 12.00 – 19.00 hrs, from Molinette Hospital, Turin, Italy. You can register for this live surgery event separately through the hospital’s website.